The CMT Research Foundation congratulates NMD Pharma and, above all, the 81 individuals who took part in the Phase 2a SYNAPSE‑CMT trial of ignaseclant for CMT1 and CMT2.

While the primary endpoint on the 6‑minute walk test was not met, it is encouraging to see consistent improvements in strength, hand function, and patient‑reported outcomes over just 21 days, with benefits persisting beyond the treatment period. These results strongly support longer‑duration studies of ignaseclant and reinforce the growing momentum toward the first approved therapies for people living with CMT. Read more: cmtrf.org/news